Growth and scale Diasend has merged with Glooko and expanded to multiple international offices (US, UK, Sweden), indicating rapid growth and an opportunity to cross-sell adjacent diabetes data management solutions to a larger global customer base.

Device interoperability The platform supports data transmission from more than 160 devices, enabling a strong value proposition for clinics seeking comprehensive data consolidation; target clinics with diverse device ecosystems for upsell of integrated data analytics.

Clinical reach Active usage by over 4,000 clinics across 23 countries in 15 languages showcases broad adoption and potential for expansion in regions with fragmented diabetes IT infrastructure.

Regulatory confidence FDA approved and CE marked solutions provide reassurance to healthcare buyers, easing procurement discussions and favoring upsell of enhanced data management and analytics features.

Financial profile Revenue in the $1M–$10M range and a lean employee base (11–50) suggest a mid-market vendor with opportunities to scale via partnerships, enterprise deals, or licensed platform expansions with larger healthcare networks.